NSE - Delayed Quote INR
Bafna Pharmaceuticals Limited (BAFNAPH.NS)
80.40
+3.48
+(4.52%)
At close: April 25 at 3:13:46 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,481,951
1,524,657
1,153,499
851,403
712,178
Cost of Revenue
1,047,167
1,069,072
765,940
512,805
454,555
Gross Profit
434,784
455,585
387,559
338,598
257,623
Operating Expense
371,871
381,583
266,875
272,514
196,242
Operating Income
62,913
74,002
120,684
66,084
61,381
Net Non Operating Interest Income Expense
-24,599
-21,650
-19,931
-7,602
-7,024
Pretax Income
42,972
73,479
116,163
52,163
58,267
Tax Provision
--
--
2,783
--
--
Net Income Common Stockholders
42,972
73,479
113,380
52,163
58,267
Diluted NI Available to Com Stockholders
42,972
73,479
113,380
52,163
58,267
Basic EPS
1.82
3.11
4.79
2.21
2.46
Diluted EPS
1.82
3.11
4.79
2.21
2.46
Basic Average Shares
23,668.76
23,656
23,656
23,656
23,685.77
Diluted Average Shares
23,668.76
23,656
23,656
23,656
23,685.77
Rent Expense Supplemental
2,492
2,099
2,053
1,920
2,066
Total Expenses
1,419,038
1,450,655
1,032,815
785,319
650,797
Net Income from Continuing & Discontinued Operation
42,972
73,479
113,380
52,163
58,267
Normalized Income
46,632
73,569
112,941.76
73,375
58,267
Interest Income
394
1,253
445
336
395
Interest Expense
22,324
19,375
17,975
5,242
886
Net Interest Income
-24,599
-21,650
-19,931
-7,602
-7,024
EBIT
65,296
92,854
134,138
57,405
59,153
EBITDA
124,753
142,808
187,482
112,338
103,935
Reconciled Cost of Revenue
1,047,167
1,069,072
765,940
512,805
454,555
Reconciled Depreciation
59,457
49,954
53,344
54,933
44,782
Net Income from Continuing Operation Net Minority Interest
42,972
73,479
113,380
52,163
58,267
Total Unusual Items Excluding Goodwill
-3,660
-90
449
-21,212
--
Total Unusual Items
-3,660
-90
449
-21,212
--
Normalized EBITDA
128,413
142,898
187,033
133,550
103,935
Tax Rate for Calcs
--
--
0
--
--
Tax Effect of Unusual Items
--
--
10.76
--
--
3/31/2021 - 11/12/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade